News

Discover the latest progress in cancer research, education and clinical care delivered by the MPCCC.

All News
December 18, 2025

Advancing Cancer Care For All Throughout 2025

A message from our Directors 

As we come to the close of another remarkable year, we want to take a moment to reflect on what has been achieved together across the Monash Partners Comprehensive Cancer Consortium (MPCCC) community.

In a year that has continued to bring both complexity and opportunity to the cancer care landscape, your commitment, expertise and collaboration have remained unwavering. From advancing research and strengthening clinical partnerships, to amplifying the consumer voice and delivering impactful events and advocacy on a local, national and global stage, 2025 has demonstrated the true power of collective effort.

We were pleased this year to secure renewed government funding for MPCCC for 2025–27, a strong endorsement of the impact of our shared work and a foundation for what comes next. This investment is enabling us to further embed and expand our networked model of support of health services, including strengthening Molecular Tumour Boards, supporting culturally safe care through Indigenous cancer clinics, and deepening partnerships with regional services so more people can access high-quality, specialist cancer care closer to home.

As we move into the next phase, this funding will allow us to build on what works, support more health services across our state, boost the availability of new treatments and clinical trials, and continue to translate our collaboration into tangible benefits for patients, families and communities. It’s an exciting time ahead of us and for the communities we serve.

We are particularly proud of the way MPCCC has continued to foster connection across our partners, bridging disciplines, institutions and perspectives, to drive meaningful progress for people affected by cancer. We know this work is not always easy. It is built on dedication, resilience and a shared belief that better outcomes are possible. We want to sincerely thank each of you: our clinicians, researchers, consumers, partners, advocates and supporters.

As we look ahead to 2026, we do so with optimism and momentum. The year ahead will bring new opportunities to deepen our impact, strengthen our partnerships and continue to lead with innovation, inclusion and purpose. On behalf of us both, thank you for being part of this important journey.

We wish you a safe, restful and well-deserved break and look forward to working alongside you in the year ahead.

Warmest wishes,

Professor Mark Shackleton and Professor Melissa Southey

MPCCC Co-Directors